Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22482090 | 0.79 | ATM (0.37) | MTNR1AMTNR1BPDK2HSD11B1 | |
| SCHEMBL22482082 | 0.79 | ATM (0.37) | MTNR1AMTNR1BPDK2HSD11B1 | |
| SCHEMBL19198696 | 0.79 | IDO1 (0.38) | TSHRPOLBMTNR1AMTNR1BKMT2A | |
| SCHEMBL23573541 | 0.77 | TNF (0.32) | PKM | |
| SCHEMBL23573544 | 0.77 | TNF (0.32) | PKM | |
| SCHEMBL24159232 | 0.76 | DGAT1 (0.31) | — | |
| SCHEMBL16144283 | 0.76 | POLB (0.37) | TSHRPOLBMTNR1AMTNR1BKMT2A | |
| SCHEMBL25854711 | 0.73 | TSHR (0.33) | TSHRPOLBMTNR1AMTNR1BKMT2A | |
| SCHEMBL19913392 | 0.72 | HSD11B1 (0.32) | GAAHSD11B1 | |
| SCHEMBL19913395 | 0.72 | HSD11B1 (0.32) | GAAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119419-A1 | BYCYCLIC JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | GAA 3433/4885TSHR 3851/4885POLB 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.